Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Capital Expenditures (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of Capital Expenditures data on record, last reported at $202000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 14.77% year-over-year to $202000.0; the TTM value through Sep 2025 reached $677000.0, down 50.0%, while the annual FY2024 figure was $1.0 million, 70.5% down from the prior year.
  • Capital Expenditures reached $202000.0 in Q3 2025 per NWBO's latest filing, down from $304000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.7 million in Q3 2021 and bottomed at $58000.0 in Q1 2022.
  • Average Capital Expenditures over 5 years is $735105.3, with a median of $408000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: tumbled 89.74% in 2022, then surged 2198.28% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $1.6 million in 2021, then surged by 39.09% to $2.2 million in 2022, then plummeted by 80.65% to $418000.0 in 2023, then plummeted by 81.34% to $78000.0 in 2024, then skyrocketed by 158.97% to $202000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $202000.0 in Q3 2025, $304000.0 in Q2 2025, and $93000.0 in Q1 2025.